| ŠANDOVÁ, Veronika, Gabriela MLADONICKÁ PAVLASOVÁ, Václav ŠEDA, Kateřina AMRUZ ČERNÁ, Sonali SHARMA, Veronika PALUŠOVÁ, Yvona BRYCHTOVÁ, Šárka POSPÍŠILOVÁ, S.M. FERNANDES, Anna PANOVSKÁ, Michael DOUBEK, M.S. DAVIDS, J.R. BROWN, Jiří MAYER and Marek MRÁZ. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K delta inhibitor idelalisib. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2021, vol. 106, No 11, p. 2995-2999. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2021.278644. |
Other formats:
BibTeX
LaTeX
RIS
@article{1813380,
author = {Šandová, Veronika and Mladonická Pavlasová, Gabriela and Šeda, Václav and Amruz Černá, Kateřina and Sharma, Sonali and Palušová, Veronika and Brychtová, Yvona and Pospíšilová, Šárka and Fernandes, S.M. and Panovská, Anna and Doubek, Michael and Davids, M.S. and Brown, J.R. and Mayer, Jiří and Mráz, Marek},
article_location = {PAVIA},
article_number = {11},
doi = {http://dx.doi.org/10.3324/haematol.2021.278644},
keywords = {COMPLEMENTEXPRESSIONRITUXIMABANTIGENCELLS},
language = {eng},
issn = {0390-6078},
journal = {haematologica},
title = {IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K delta inhibitor idelalisib},
url = {https://haematologica.org/article/view/haematol.2021.278644},
volume = {106},
year = {2021}
}
TY - JOUR
ID - 1813380
AU - Šandová, Veronika - Mladonická Pavlasová, Gabriela - Šeda, Václav - Amruz Černá, Kateřina - Sharma, Sonali - Palušová, Veronika - Brychtová, Yvona - Pospíšilová, Šárka - Fernandes, S.M. - Panovská, Anna - Doubek, Michael - Davids, M.S. - Brown, J.R. - Mayer, Jiří - Mráz, Marek
PY - 2021
TI - IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K delta inhibitor idelalisib
JF - haematologica
VL - 106
IS - 11
SP - 2995-2999
EP - 2995-2999
PB - FERRATA STORTI FOUNDATION
SN - 03906078
KW - COMPLEMENTEXPRESSIONRITUXIMABANTIGENCELLS
UR - https://haematologica.org/article/view/haematol.2021.278644
N2 - Efforts to combine anti-CD20 antibodies (such as rituximab or obinutuzumab) with BCR inhibitors or venetoclax lead to the necessity to better understand the largely unclear mechanisms of CD20 regulation and its function (s) (reviewed in Pavlasova and Mraz1). This is underscored by the observation that in chronic lymphocytic leukemia (CLL) the combination of ibrutinib with rituximab fails to provide a clinical benefit in comparison to ibrutinib alone2 likely as ibrutinib downmodulates CD20 levels.1,3-5 PI3Kδ inhibitor idelalisib has been approved in combination with rituximab or ofatumumab;6 however, it remains unclear if idelalisib affects CD20 levels or function (s). Here we show for the first time that single-agent idelalisib therapy in CLL leads to CD20 downmodulation in vivo by interfering with a previously unknown mechanism of CD20 transcriptional regulation via the IL4- STAT6 axis. We describe a novel mechanism of CD20 regulation in CLL B cells, which has implications for combinatorial therapy with PI3K inhibitors.
ER -
ŠANDOVÁ, Veronika, Gabriela MLADONICKÁ PAVLASOVÁ, Václav ŠEDA, Kateřina AMRUZ ČERNÁ, Sonali SHARMA, Veronika PALUŠOVÁ, Yvona BRYCHTOVÁ, Šárka POSPÍŠILOVÁ, S.M. FERNANDES, Anna PANOVSKÁ, Michael DOUBEK, M.S. DAVIDS, J.R. BROWN, Jiří MAYER and Marek MRÁZ. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K delta inhibitor idelalisib. \textit{haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2021, vol.~106, No~11, p.~2995-2999. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2021.278644.
|
